The Cremins lab investigates the epigenetic mechanisms regulating development and function of the mammalian central nervous system. We map and analyze neuronal epigenomes in three-dimensions using quantitative, genome-wide technologies. We also perturb epigenomes by employing state-of-the art genetic engineering strategies (e.g. CRISPR/Cas9, optoepigenetics). To test our hypotheses, we primarily use embryonic and induced pluripotent stem cell models of neuronal differentiation and disease. Our long-term goal is to discover how genome architecture controls genome function, applying this to study fundamental mechanisms controlling neuronal phenotype and, by extension, the onset and progression of neurodegenerative and neurodevelopmental disease states.

Linda Zhou, PhD wins the Saul Winegrad award for 2021 best thesis for Penn GCB.

Congratulations to Linda, Ken, Thomas, Chunmin, Ji Hun, Wanfeng, Kate, and Chuanbin for the posting of their new manuscript to BioRxiv.

Michael Guo wins an R25 NIH physician-scientist fellowship. Congratulations Mike!

The Lab has officially moved to a new lab space in the Clinical Research Building!

Lab receives two U01 grants from the 4D Nucleome Consortium.

The lab receives a grant from the Friedreich’s Ataxia Research Alliance.

Linda Zhou passes her PhD defense with flying colors. Congratulations Dr. Zhou!

Spencer Hawes has decided to join lab!



Our work is supported by the New York Stem Cell Foundation, the Alfred P. Sloan Foundation, the National Science Foundation, an NIH New Innovator Award through the National Institute of Mental Health and the NIH 4D Nucleome Common Fund Initiative.